Transcript: Certara Q2 2026 Earnings Conference Call

Certara (NASDAQ: CERT ) reported second-quarter financial results on Tuesday.

The transcript from the company's second-quarter earnings call has been provided below.

This content is powered APIs.

For comprehensive financial data and transcripts, visit Access the full call at Summary Certara reported Q2 2026 revenue of $93.3 million, a year-over-year growth of 1%, with software revenue increasing by 4% and service revenue declining by 3%.

The company reaffirmed its full-year 2026 revenue growth guidance of 0% to 4%, focusing on improving software performance and addressing service challenges.

Strategic initiatives include a reorganization into two business units (MIDD and ACE), divesting the regulatory and medical writing business, and appointing a new Chief Commercial Officer to enhance the go-to-market strategy.

Certara is leveraging AI to enhance product development and operational efficiency, with significant AI-driven improvements in software development and scientific service delivery.

The company announced a new partnership with Nvidia to integrate AI into its software offerings, aiming to expand use cases and improve client engagement.

Certara completed a $100 million share repurchase program and initiated a new $50 million program, reflecting confidence in its strategy and financial position.

Operational highlights include the divestiture of the Maze business, introduction of new AI capabilities, and expansion into international markets including China and Japan.

Full Transcript OPERATOR Following the speakers' presentation, there will be a question-and-answer session.

Please be advised that today's conference is being recorded.

I would now like to hand the conference over to Jay Lu, Investor Relations at LifeSci.

Please go ahead.

Jay Lu, Investor Relations at LifeSci Good morning, everyone.

Thank you all for participating in today's conference call.

On the call from Certara we have John Resnik, Chief Executive Officer, and Faiz Mohammed, Interim Chief Financial Officer.

Earlier today, Certara released financial results for the quarter ended June 30, 2026.

A copy of the press release is available on the company's website.

Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements and actual results may differ materially from those expressed or implied in the forward-looking statements.

Please refer to Slide 2 in the accompanying presentation titled Second Quarter 2026 Financial Results for additional information, which you can find on the company's investor relations website.

In their remarks or responses to questions, management may mention some non-GAAP financial measures.

Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are available in the recent earnings press release available on the company's website.

Please refer to the reconciliation tables in the accompanying materials for additional information.

This conference call contains time-sensitive information and is accurate only as of today, August 4, 2026.

Certara disclaims any obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise.

And with that, I will turn the call over to John.

John Resnik, Chief Executive Officer Thank you for joining today's call.

Before I get into our results, I want to highlight the appointment of our new Chief Commercial Officer, which we announced earlier this morning.

This reflects our commitment to a new, more impactful go-to-market approach, which I'll cover in more detail shortly.

The second quarter was about executing on our commitments.

Overall, we are pleased with our progress.

We are transforming Certara into a company we believe is capable of delivering sustainable double-digit growth.

We still have work to do, but we are on the right path.

We are executing against our plan.

Our foundation is strengthening, and the macro market conditions—biopharma spending, clinical trial starts, and new regulatory guidance—continue to be in our favor.